Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
National Cancer Institute, Rio de Janeiro, RJ, Brazil.
J Oncol Pharm Pract. 2023 Oct;29(7):1725-1735. doi: 10.1177/10781552231189864. Epub 2023 Aug 1.
Cachexia is associated with increased morbidity and mortality rates in patients with cancer. This meta-analysis aims to explore the effect of anamorelin on cancer cachexia markers.
We searched MEDLINE/PubMed, SCOPUS, and WOS from their inception until 5 June 2022. A systematic search was conducted according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines. We included trials investigating the effect of anamorelin on body weight, lean body mass, fat mass, insulin-like growth factor 1 (IGF-1), handgrip, quality of life insulin-like growth factor-binding protein 3 (IGFBP-3), and in patients with cancer. A random-effects model was run to pooled results.
Five articles providing 1331 participants were analyzed in this study. Pooled analysis revealed a significant increase in body weight (weighted mean difference (WMD): 1.56 kg, 95% confidence interval (CI): 1.20, 1.92; = 0%), lean body mass (WMD: 1.36 kg, 95% CI: 0.85, 1.86; = 53.1%), fat mass (WMD: 1.02 kg, 95% CI: 0.51, 1.53; = 60.7%), IGF-1 (WMD: 51.16 ng/mL, 95% CI: 41.42, 60.90, = 0%), and IGFBP-3 (WMD: 0.43 μg/mL, 95% CI: 0.17, 0.68, = 98.6%). Results showed no significant increase in appetite when analysis run on all studies without considering different doses 0.29 (95% CI: -0.30, 0.89, = 73.8%), however, there was a significant increase in appetite without heterogeneity and inconsistency 0.59 (95% CI: 0.32, 0.86; = 0%) in the 100 mg/day group compared to anamorelin non-user.
Patients with cancer who receive anamorelin as a treatment for cachexia showed a significant increase in body weight, lean body mass, fat mass, IGF-1, and IGFBP-3.
恶病质与癌症患者的发病率和死亡率增加有关。本荟萃分析旨在探讨 anamorelin 对癌症恶病质标志物的影响。
我们检索了 MEDLINE/PubMed、SCOPUS 和 WOS 自成立至 2022 年 6 月 5 日的数据。根据系统评价和荟萃分析的首选报告项目 (PRISMA) 指南进行了系统搜索。我们纳入了研究 anamorelin 对体重、去脂体重、体脂、胰岛素样生长因子 1 (IGF-1)、握力、生活质量、胰岛素样生长因子结合蛋白 3 (IGFBP-3)影响的试验，纳入了癌症患者。使用随机效应模型对结果进行汇总分析。
本研究共纳入 5 项研究，共 1331 名参与者。荟萃分析显示体重（加权均数差（WMD）：1.56kg，95%置信区间（CI）：1.20，1.92；=0%）、去脂体重（WMD：1.36kg，95%CI：0.85，1.86；=53.1%）、体脂（WMD：1.02kg，95%CI：0.51，1.53；=60.7%）、IGF-1（WMD：51.16ng/mL，95%CI：41.42，60.90；=0%）和 IGFBP-3（WMD：0.43μg/mL，95%CI：0.17，0.68；=98.6%）显著增加。当分析不考虑不同剂量时，所有研究均显示食欲无显著增加（0.29，95%CI：-0.30，0.89；=73.8%），然而，与 anamorelin 非使用者相比，100mg/天组的食欲显著增加（0.59，95%CI：0.32，0.86；=0%），且无异质性和不一致性。
接受 anamorelin 治疗恶病质的癌症患者体重、去脂体重、体脂、IGF-1 和 IGFBP-3 均显著增加。
